Supplementary Materials

Supplementary Material for:

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

Emma Nolan, Peter Savas, Antonia N. Policheni, Phillip K. Darcy, François Vaillant, Christopher P. Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia-Min B. Pang, Stephen B. Fox, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Charles M. Perou, Jane E. Visvader, Daniel H. D. Gray, Sherene Loi,* Geoffrey J. Lindeman*

*Corresponding author. Email: sherene.loi{at}petermac.org (S.L.); lindeman{at}wehi.edu.au (G.J.L.)

Published 7 June 2017, Sci. Transl. Med. 9, eaal4922 (2017)
DOI: 10.1126/scitranslmed.aal4922

This PDF file includes:

  • Fig. S1. Characterization of TILs in BRCA1- and BRCA2-mutant tumors by OPAL imaging.
  • Fig. S2. Output from deconstructSigs for a representative MMTV-cre/Brca1fl/flp53+/− tumor.
  • Fig. S3. Effect of combination therapy with checkpoint inhibitors on mice body weight, blood count, and biochemistry.
  • Fig. S4. Cisplatin treatment and induction of immunogenicity markers on human TNBC BRCA1-mutated HCC1937 tumors in vitro.
  • Fig. S5. Characterization of lymphocyte subsets in response to immune checkpoint inhibitor therapy.
  • Fig. S6. Effect of combination therapy with checkpoint inhibitors on the growth of Brca1-deficient tumors in RAG1 mice.
  • Fig. S7. Dual checkpoint inhibitor blockade and activation of dendritic cells and polyfunctional effector T cells.
  • Fig. S8. Characterization of lymphocyte subsets in response to immune checkpoint inhibitor therapy.

[Download PDF]